Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates
Mirati Therapeutics (NASDAQ: MRTX) will announce its financial results for Q2 2022 and corporate updates on August 3, 2022, at 4:30 p.m. ET. A conference call will provide insights into the company's performance and future direction. Investors can tune in via webcast or through specified phone lines. Mirati is focused on developing innovative therapies for cancer, particularly targeting genetic drivers of the disease.
- Company is focused on high unmet medical needs in cancer treatment.
- Mirati is advancing a pipeline of novel therapeutics.
- Forward-looking statements carry inherent risks and uncertainties regarding drug development.
- Dependence on successful commercialization of new drug products is uncertain.
SAN DIEGO, July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with recent corporate updates on August 3, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 3, company executives will provide company updates and review financial results.
Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 313-209-4906 or international +1 877-502-9276, confirmation code: 1791105. A replay of the call will be available approximately 2 hours after the event has ended at the same website.
Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet medical need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer. For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook.
This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation adagrasib (selective KRASG12C inhibitor), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA cooperative PRMT5 inhibitor), MRTX1133 (selective KRASG12D inhibitor), and MRTX0902 (SOS1 inhibitor), is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the "SEC") available at the SEC's Internet site (www.sec.gov). Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-to-report-second-quarter-2022-financial-results-and-recent-corporate-updates-301590366.html
SOURCE Mirati Therapeutics, Inc.
FAQ
When will Mirati Therapeutics announce its Q2 2022 financial results?
How can I listen to the Mirati Therapeutics conference call?
What is Mirati Therapeutics' focus?
What date is the Mirati Therapeutics conference call scheduled for?
